Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

GeneDx Holdings (WGS) Return on Sales: 2021-2025

Historic Return on Sales for GeneDx Holdings (WGS) over the last 5 years, with Sep 2025 value amounting to 0.01%.

  • GeneDx Holdings' Return on Sales rose 32.00% to 0.01% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.01%, marking a year-over-year increase of 32.00%. This contributed to the annual value of -0.17% for FY2024, which is 70.00% up from last year.
  • As of Q3 2025, GeneDx Holdings' Return on Sales stood at 0.01%, which was up 33.46% from 0.00% recorded in Q2 2025.
  • GeneDx Holdings' Return on Sales' 5-year high stood at 0.01% during Q3 2025, with a 5-year trough of -2.38% in Q1 2023.
  • Over the past 3 years, GeneDx Holdings' median Return on Sales value was -0.48% (recorded in 2024), while the average stood at -0.84%.
  • Its Return on Sales has fluctuated over the past 5 years, first tumbled by 173bps in 2023, then skyrocketed by 191bps in 2024.
  • Over the past 5 years, GeneDx Holdings' Return on Sales (Quarterly) stood at -1.16% in 2021, then tumbled by 118bps to -2.34% in 2022, then soared by 147bps to -0.87% in 2023, then surged by 70bps to -0.17% in 2024, then spiked by 32bps to 0.01% in 2025.
  • Its Return on Sales was 0.01% in Q3 2025, compared to 0.00% in Q2 2025 and -0.12% in Q1 2025.